e-Therapeutics plc Exercise of Options and Issue of Equity (5174U)
28 Marzo 2023 - 8:57AM
UK Regulatory
TIDMETX
RNS Number : 5174U
e-Therapeutics plc
28 March 2023
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
EXERCISE OF OPTIONS AND ISSUE OF EQUITY
LONDON, UK, 28 March 2023 - e-therapeutics plc (AIM: ETX), the
drug discovery company, announces that it has allotted 500,000 new
ordinary shares of 0.1p each in the Company (the "New Ordinary
Shares") following the exercise of share options at 2.8p per New
Ordinary Share by a former employee.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 11 April 2023. The New
Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 582,659,332. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
For further information, please contact:
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
James Chandler, VP IR & Communications 8888
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc www.etherapeutics.co.uk
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary Computational Biology Platform enables the
generation and analysis of biological network models, providing a
novel and mechanistic approach to drug discovery that explicitly
considers the true complexity of biology and makes more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data and information resource. The
Company generates, prioritises and tests millions of hypotheses in
silico to identify better therapeutic targets with higher
confidence.
ETX's proprietary RNAi Platform enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by ETX's Computational Biology
Platform. The focus on hepatocytes offers the opportunity to work
across a wide variety of diseases. The liver is a highly
metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of
action.
ETX is progressing a pipeline of first-in-class pre-clinical
RNAi candidates in several therapeutic areas including haematology,
cardiovascular disease and non-alcoholic steatohepatitis ("NASH").
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. e-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEKZGZFDRDGFZM
(END) Dow Jones Newswires
March 28, 2023 10:57 ET (14:57 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024